The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
|
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [11] A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
    van Eyk, Huub J.
    Paiman, Elisabeth H. M.
    Bizino, Maurice B.
    de Heer, Paul
    Geelhoed-Duijvestijn, Petronella H.
    Kharagjitsingh, Aan V.
    Smit, Johannes W. A.
    Lamb, Hildo J.
    Rensen, Patrick C. N.
    Jazet, Ingrid M.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [12] Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial
    Snaith, Jennifer R.
    Samocha-Bonet, Dorit
    Evans, Jennifer
    Liu, Zhixin
    Kowalski, Greg
    Bruce, Clinton
    Holmes-Walker, Deborah J.
    Greenfield, Jerry R.
    DIABETIC MEDICINE, 2021, 38 (09)
  • [13] Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
    Martorina, Wagner
    Tavares, Almir
    JMIR RESEARCH PROTOCOLS, 2023, 12
  • [14] Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial
    Kim, Nam Hoon
    Kim, Hee Young
    An, Hyonggin
    Seo, Ji A.
    Kim, Nan Hee
    Choi, Kyung Mook
    Baik, Sei Hyun
    Choi, Dong Seop
    Kim, Sin Gon
    DIABETOLOGY & METABOLIC SYNDROME, 2013, 5
  • [15] Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial
    Alokail, Majed S.
    Sabico, Shaun
    Al-Saleh, Yousef
    Al-Daghri, Nasser M.
    Alkharfy, Khalid M.
    Vanhoutte, Paul M.
    McTernan, Philip G.
    TRIALS, 2013, 14
  • [16] Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Barzilai, Nir
    Guo, Hua
    Mahoney, Erin M.
    Caporossi, Suzanne
    Golm, Gregory T.
    Langdon, Ronald B.
    Williams-Herman, Debora
    Kaufman, Keith D.
    Amatruda, John M.
    Goldstein, Barry J.
    Steinberg, Helmut
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 1049 - 1058
  • [17] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week,double-blind, placebo-controlled trial
    Strojek, K.
    Yoon, K. H.
    Hruba, V.
    Elze, M.
    Langkilde, A. M.
    Parikh, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 : S16 - S26
  • [18] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
    Strojek, K.
    Yoon, K. H.
    Hruba, V.
    Elze, M.
    Langkilde, A. M.
    Parikh, S.
    DIABETES OBESITY & METABOLISM, 2011, 13 (10) : 928 - 938
  • [19] Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Zhang, Bo
    Cheng, Zhifeng
    Chen, Ji
    Zhang, Xin
    Liu, Dexue
    Jiang, Hongwei
    Ma, Guoqing
    Wang, Xiaoyun
    Gan, Shenglian
    Sun, Juan
    Jin, Ping
    Yi, Jianjun
    Shi, Bimin
    Ma, Jianhua
    Ye, Shandong
    Wang, Guixia
    Ji, Linong
    Gu, Xuejiang
    Yu, Ting
    An, Pei
    Deng, Huan
    Li, Haoyu
    Li, Li
    Ma, Qingyang
    Qian, Lei
    Yang, Wenying
    DIABETES CARE, 2024, 47 (01) : 160 - 168
  • [20] Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients
    Bonfigli, A. R.
    Boemi, M.
    Festa, R.
    Bonazzi, P.
    Brandoni, G.
    Spazzafumo, L.
    Olivieri, F.
    Ceriello, A.
    Genovese, S.
    Testa, R.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (10) : 893 - 898